Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Capecitabine in Elderly Metastatic Breast Cancer
NCT01195298Phase 2Unknown
- Sponsor
- South Eastern European Research Oncology Group
- Start
- May 2010
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by South Eastern European Research Oncology Group. Primary endpoint: Time to treatment progression at 5 years. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01195298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195298.